Clinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Recent data indicate that more than 65% of patients with major depressive disorder (MDD) fail to achieve remission. This article reviews research on the current understanding and management of residual symptoms, i.e., subthreshold depressive symptoms present after recovery from a major depressive episode. DATA SOURCES: MEDLINE (1966 to June 2006) was searched using combinations of the following search terms: major depressive disorder, residual symptoms, remission, response, tachyphylaxis, antidepressant, algorithm, treatment, responsiveness, serotonin, norepinephrine, and dopamine. STUDY SELECTION: All relevant articles that were published in English and reported original study data related to residual symptoms in MDD were included. DATA EXTRACTION: Studies were examined for data related to the prevalence, presentation, consequences, treatment, and neurobiological underpinnings of residual symptoms associated with MDD. DATA SYNTHESIS: Residual symptoms are common among patients treated for MDD who do not achieve full remission. Incomplete remission is associated with increased risk of relapse, suicide, functional impairment, and higher use of health care resources. Several factors, including "downstream" neurochemical mechanisms and clinical factors such as lack of adherence, contribute to the high prevalence of residual symptoms. Various clinical strategies, including switching and substitution antidepressant therapies, are used to address unresolved depressive symptoms. Individual differences in therapeutic response contribute to inadequate treatment and are linked to numerous clinical and neurobiological factors, including noncompliance, underdosing, intolerance, disturbances in neural circuitry, and genetic variability in neurotransmitters. CONCLUSIONS: Future research is needed to more precisely characterize residual symptoms and their underlying biochemical and molecular mechanisms in order to develop more effective treatment methods.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are three broad disease models proposed by the literature to explain treatment resistance, summarised in Figure 5 (see eAppendix 3 for search details). 48–51”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [49]
Citations
Cites
Still being checked.
Cited by
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
“Purely serotonergic activity lowers dopamine and norepinephrine levels via effects on 5-HT2C and 5-HT2A interneurons, respectively [83].”
BackgroundMcMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Metadata
- Authors
- Trivedi, M. H., Hollander, E., Nutt, D., & Blier, P.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Bristol (GB)
- University of Ottawa (CA)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-02-15
- Volume
- 69
- Issue
- 2
- Pages
- 246-258
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2041144155
- Cited by
- 153
- References
- 0
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 9 · 2015: 9 · 2014: 11 · 2013: 12 · 2012: 9
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- residual depressive symptoms, major depressive disorder, incomplete remission, antidepressant response, antidepressant switching, tachyphylaxis, medication adherence, underdosing, relapse risk, suicide risk, functional disability, health care utilization, neurobiological mechanisms, serotonin, norepinephrine, dopamine, neural circuits
- MeSH terms
- Algorithms, Antidepressive Agents, Anxiety, Cognition Disorders, Decision Trees, Depression, Depressive Disorder, Dopamine, Humans, Hypothalamo-Hypophyseal System, Norepinephrine, Pituitary-Adrenal System, Serotonin, Sleep Wake Disorders, Neurotransmitter Uptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Adrenergic Uptake Inhibitors, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression. https://app.cochat.ai/papers/10.4088/jcp.v69n0211
- The paper
- Trivedi, M. H., Hollander, E., Nutt, D., & Blier, P. (2008). Clinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v69n0211
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.